Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.

about

Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q47148072

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.

@en

Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.

@nl

type

Item

label

Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.

@en

Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.

@nl

prefLabel

Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.

@en

Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.

@nl

P1476

Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.

@en

P2093

Alex A Adjei

http://www.w3.org/2001/XMLSchema#string

Hao Xie

http://www.w3.org/2001/XMLSchema#string

P2860

Pembrolizumab for the treatment of non-small-cell lung cancer

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.

P304

S41-S43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.21037/TLCR.2017.10.15

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29299408

http://www.w3.org/2001/XMLSchema#string

P932

5750158

http://www.w3.org/2001/XMLSchema#string